Cellis was pleased to participate in the JLABS EMEA CEO Summit 2026 in London, represented by our CEO, Robert Aleksandrowicz, and our CSO, Prof. Magdalena Król The event brought together founders, CEOs, investors, Johnson & Johnson experts, and biotechnology leaders from across Europe to discuss the opportunities and challenges shaping the future of life sciences innovation.
The Summit provided a unique forum for exchanging experiences on company growth, strategic partnerships, fundraising, and clinical development. Discussions highlighted the importance of building collaborations early, preparing robust development strategies, and maintaining a global perspective from the earliest stages of company growth.
A key theme throughout the event was the rapidly evolving international biotechnology landscape. Sessions explored how European innovators can strengthen their competitiveness by focusing on scientific differentiation, strategic execution, and international collaboration. Participants also discussed emerging trends in global investment and the increasing importance of cross-border partnerships in accelerating the development of novel therapies.
For Cellis, participation in the Summit represented an excellent opportunity to engage with leaders across the biotechnology ecosystem while sharing perspectives on the translation of innovative science into clinical applications. As the company continues to advance its proprietary macrophage-based therapeutic platform for oncology, interactions with industry experts and fellow innovators remain an important part of shaping its long-term development strategy.
“Great ideas move faster when the right people are in the same room. The JLABS EMEA CEO Summit was exactly that kind of place,” said Prof. Magdalena Król.
Cellis would like to thank the JLABS EMEA team for organizing a highly engaging event and creating an environment that fostered meaningful dialogue across the European biotechnology community. We look forward to continuing these conversations and strengthening collaborations that support the development of next-generation cancer therapies.
